Related Experiment Video

Updated: Jun 23, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Is there an emerging role for neoadjuvant targeted therapy in renal cell carcinoma?

M Maruschke1, O W Hakenberg

  • 1Department of Urology, Rostock University, Rostock, Germany.

Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology
|May 20, 2009
PubMed

Insights

Neoadjuvant targeted therapies may shrink locally advanced kidney tumors, facilitating surgery. However, their impact on patient survival and quality of life remains unproven.

Area of Science:

  • Oncology
  • Nephrology
  • Surgical Oncology

Background:

  • Metastatic renal cell carcinoma treatments are evolving.
  • Locally advanced renal tumors present surgical challenges.
  • Neoadjuvant therapies are being explored for down-sizing tumors.

Purpose of the Study:

  • To investigate the feasibility and impact of neoadjuvant targeted therapies for locally advanced renal tumors.
  • To assess the effect of neoadjuvant treatment on subsequent surgical tumor removal.
  • To evaluate the potential benefits of neoadjuvant therapy on patient survival and quality of life.

Main Methods:

  • Review of case reports on neoadjuvant therapy for renal cell carcinoma.
  • Analysis of small surgical series examining tumor removal post-neoadjuvant treatment.

Main Results:

  • Case reports suggest down-sizing of large renal carcinomas is feasible with neoadjuvant therapy.
  • Small surgical series indicate that neoadjuvant treatment does not impair subsequent tumor removal.
  • Current evidence is insufficient to determine the impact on survival or quality of life.

Conclusions:

  • Neoadjuvant targeted therapies show promise for down-sizing locally advanced renal tumors.
  • Surgical removal of renal tumors appears feasible after neoadjuvant treatment.
  • Further research is required to establish the long-term benefits of neoadjuvant therapy in renal cell carcinoma.

More Related Videos

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living donor...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.